Position: Doctoral Student – Molecular and Cellular Oncology

Department: Translational Oncology

Code number: 2018-0261

The German Cancer Research Center is the largest biomedical research institution in Germany. With approximately 3,000 employees, we operate an extensive scientific program in the field of cancer Research.

Job description:

We are interested in discovering and characterizing specific vulnerabilities in cancer cells that can be exploited for the development of targeted therapies. To achieve this goal, we use a broad spectrum of molecular and cell biological technologies, such as RNA interference or CRISPR/Cas9-mediated genome editing on small and large scale in combination with the analysis of diverse in vitro and in vivo phenotypic readouts. Examples include RNAi screening in leukemia and solid cancers (e.g. Cell. 2009 May 29;137(5):821-34; Blood. 2014 Jul 3;124(1):13-23; Leukemia. 2018 Mar 22 [Epub ahead of print]), and cancer genome sequencing combined with functional testing (e.g. Cancer Discov. 2018 Sep;8(9):1087-1095).  

The candidate will study the functional and mechanistic consequences of GATA2 loss in human models of GATA2-haploinsufficient acute myeloid leukemia and conduct unbiased functional genomic screens for conditional synthetic lethal interactions with GATA2 haploinsufficiency using genome-scale CRISPR technology. In addition, a project with focus on the characterization of genome-wide epigenetic changes driven by mutant KRAS in lung and pancreatic carcinogenesis is available.

We are an international, friendly and enthusiastic team that offers intensive support and mentoring. Technologies in our laboratory include functional genomics, structural genomics (including whole-exome/genome, RNA and single-cell RNA sequencing), bioinformatics and diverse molecular/cell biological and biochemical approaches. Furthermore, we are closely connected to clinical aspects of cancer patient care, for example via the MASTER cancer genome sequencing program of the National Center for Tumor Diseases (NCT) and the German Cancer Consortium (DKTK). The candidate will be co-supervised by Prof. Stefan Fröhling and Prof. Claudia Scholl (DKFZ and NCT Heidelberg).


  • We are looking for a brilliant early-career scientist who is highly motivated, ambitious and hard-working.
  • Applicants should hold a Diploma/Master’s degree in biology, biochemistry, genetics or a related field.
  • Expertise in molecular and cellular biology, with specific focus on genome engineering techniques is advantageous.
  • Profound knowledge of cancer biology, excellent communication skills and proficiency in English are mandatory.

Applications must include a CV, cover letter, certificates, expected availability date, a complete list of publications and 2-3 reference letters.

We offer:

  • Interesting, versatile workplace
  • International, attractive working environment
  • Campus with modern state-of-the-art infrastructure
  • Access to international research networks
  • Doctoral student payment including social benefits
  • Flexible working hours
  • Comprehensive training and mentoring program through the Helmholtz International Graduate School

Earliest Possible Start Date: as soon as possible

Duration: The position is limited to 3 years with the possibility of prolongation.

Application Deadline: 27.11.2018


Mr Prof. Dr. med. Stefan Fröhling
Phone +49 (0)6221/42-1634

Please note that we do not accept applications submitted via email.

The German Cancer Research Center is committed to increase the percentage of female scientists and encourages female applicants to apply. Among candidates of equal aptitude and qualifications, a person with disabilities will be given preference.                           

To apply for a position please use our online application portal (www.dkfz.de/jobs).

We ask for your understanding that we cannot return application documents that are sent to us by post (Deutsches Krebsforschungszentrum, Personalabteilung, Im Neuenheimer Feld 280, 69120 Heidelberg) and that we do not accept applications submitted via email. We apologize for any inconvenience this may cause.